Kura Oncology to Report Third Quarter 2025 Financial Results
Kura Oncology (Nasdaq: KURA) will report third quarter 2025 financial results on Tuesday, November 4, 2025 before U.S. markets open. Management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss results and provide a corporate update.
The live webcast and archived replay will be available on the company’s investor relations website at www.kuraoncology.com.
Kura Oncology (Nasdaq: KURA) will report terzo trimestre 2025 risultati finanziari su martedì 4 novembre 2025 prima dell'apertura dei mercati statunitensi. Il management terrà una conference call e webcast alle 8:00 a.m. ET / 5:00 a.m. PT per discutere i risultati e fornire un aggiornamento aziendale.
Il webcast in diretta e la replica archiviata saranno disponibili sul sito di relazioni con gli investitori della società all'indirizzo www.kuraoncology.com.
Kura Oncology (Nasdaq: KURA) reportará los resultados del tercer trimestre de 2025 el martes 4 de noviembre de 2025 antes de la apertura de los mercados de EE. UU. La dirección realizará una conferencia telefónica y un webcast a las 8:00 a.m. ET / 5:00 a.m. PT para discutir los resultados y proporcionar una actualización corporativa.
El webcast en vivo y la repetición archivada estarán disponibles en el sitio de relaciones con inversionistas de la empresa en www.kuraoncology.com.
Kura Oncology(Nasdaq: KURA)는 2025년 3분기 실적을 미국 시장 개장 전 화요일, 2025년 11월 4일에 발표합니다. 경영진은 동부 표준시 8:00 / 태평양 표준시 5:00에 컨퍼런스 콜과 웹캐스트를 주최하여 실적과 기업 업데이트를 논의합니다.
생중계 및 아카이브 재방송은 회사의 투자자 관계 웹사이트 www.kuraoncology.com에서 이용 가능합니다.
Kura Oncology (Nasdaq: KURA) publiera les résultats financiers du troisième trimestre 2025 le mardi 4 novembre 2025, avant l'ouverture des marchés américains. La direction animera une conférence téléphonique et un webcast à 8h00 HE / 5h00 HP pour discuter des résultats et fournir une mise à jour de l'entreprise.
Le webcast en direct et la rediffusion seront disponibles sur le site des relations investisseurs de l'entreprise à www.kuraoncology.com.
Kura Oncology (Nasdaq: KURA) wird die Finanzergebnisse des dritten Quartals 2025 am Dienstag, den 4. November 2025 vor der Eröffnung der US-Märkte bekannt geben. Das Management wird eine Telefonkonferenz und einen Webcast um 8:00 Uhr ET / 5:00 Uhr PT abhalten, um Ergebnisse zu besprechen und ein Unternehmensupdate zu geben.
Der Live-Webcast und die archivierte Wiedergabe stehen auf der Investor Relations-Website des Unternehmens unter www.kuraoncology.com zur Verfügung.
Kura Oncology (Nasdaq: KURA) ستعلن عن نتائجها المالية للربع الثالث من 2025 في يوم الثلاثاء 4 نوفمبر 2025 قبل افتتاح أسواق الولايات المتحدة. ستعقد الإدارة مكالمة مؤتمر وبث ويب في الساعة 8:00 صباحاً بتوقيت شرق الولايات المتحدة / 5:00 صباحاً بتوقيت المحيط الهادئ لمناقشة النتائج وتقديم تحديث للشركة.
سيكون البث المباشر والنسخة المسجلة متاحين على موقع علاقات المستثمرين للشركة في www.kuraoncology.com.
Kura Oncology（纳斯达克代码：KURA） 将于 2025年第三季度 财报在美国市场开盘前的 2025年11月4日（星期二） 公布。管理层将于 东部时间上午8:00 / 太平洋时间上午5:00 举行电话会议和网络直播，讨论业绩并提供公司更新。
现场网络直播和归档回放将可在公司投资者关系网站 www.kuraoncology.com 获取。
- None.
- None.
SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report third quarter 2025 financial results on Tuesday, November 4, 2025, before the U.S. financial markets open. Kura’s management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss the financial results and provide a corporate update.
The live webcast and archived replay of the event may be accessed on the investor relations section of the Company’s website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias, and continues to pioneer advancements in menin inhibition for acute leukemias and solid tumors and in farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Contacts
Investors and media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
FAQ
When will KURA report third quarter 2025 financial results?
What time is the KURA Q3 2025 conference call and webcast?
Where can I access the KURA live webcast and replay for Q3 2025?
Will KURA management provide a corporate update during the Q3 2025 call?
Is the KURA Q3 2025 report timed before U.S. market open?
